Abstract
The current pandemic of coronavirus disease (COVID-19) caused by SARS-CoV-2 is a significant global health challenge. A recent study by Carvelli and colleagues now demonstrates the involvement of complement C5a and its receptor C5aR1 in disease progression and suggests that blockade of the C5a-C5aR1 axis may represent a potential therapeutic strategy against COVID-19.
Keywords:
COVID-19; GPCRs; SARS-CoV-2; cellular signaling; complement system; drug discovery.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / pharmacology
-
Betacoronavirus / drug effects
-
Betacoronavirus / immunology*
-
Betacoronavirus / physiology
-
COVID-19
-
Complement C5a / immunology*
-
Complement C5a / metabolism
-
Coronavirus Infections / immunology*
-
Coronavirus Infections / therapy
-
Coronavirus Infections / virology
-
Disease Models, Animal
-
Humans
-
Pandemics
-
Pneumonia, Viral / immunology*
-
Pneumonia, Viral / therapy
-
Pneumonia, Viral / virology
-
Receptor, Anaphylatoxin C5a / immunology*
-
Receptor, Anaphylatoxin C5a / metabolism
-
Receptors, G-Protein-Coupled / immunology
-
Receptors, G-Protein-Coupled / metabolism
-
SARS-CoV-2
-
Signal Transduction / drug effects
-
Signal Transduction / immunology
Substances
-
Antibodies, Monoclonal
-
C5AR1 protein, human
-
Receptor, Anaphylatoxin C5a
-
Receptors, G-Protein-Coupled
-
Complement C5a